US 12,102,693 B1
Pharmaceutical composition with nanoparticle-based drug delivery combined with non-invasive radiographic monitoring model
Joe G. Assouline, Coralville, IA (US); and Sean K. Sweeney, Coralville, IA (US)
Assigned to NANOMEDTRIX, LLC, Coralville, IA (US)
Filed by NANOMEDTRIX, LLC, Coralville, IA (US)
Filed on Aug. 25, 2023, as Appl. No. 18/456,300.
Int. Cl. A61K 9/51 (2006.01); A61K 9/00 (2006.01); A61K 31/00 (2006.01); A61K 31/337 (2006.01); A61K 31/407 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 49/00 (2006.01); A61K 49/08 (2006.01); A61K 49/22 (2006.01); A61P 35/00 (2006.01)
CPC A61K 49/0002 (2013.01) [A61K 9/0053 (2013.01); A61K 9/5115 (2013.01); A61K 31/337 (2013.01); A61K 31/407 (2013.01); A61K 31/658 (2023.05); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 49/0093 (2013.01); A61K 49/085 (2013.01); A61K 49/225 (2013.01); A61P 35/00 (2018.01)] 10 Claims
 
1. An orally administered pharmaceutical composition comprising:
a mesoporous silica nanoparticle (“MSN”);
a bioactive agent loaded into the MSN; and
a polymeric enteric coating encapsulating the surface of the MSN configured to prevent release of the bioactive agent in a stomach of a patient;
a contrast agent covalently linked with the polymeric enteric coating to the MSN; and
a first pharmaceutical composition comprising the first mesoporous silica nanoparticle (“MSN”), the first bioactive agent comprising a first chemotherapeutic agent loaded into the first MSN, the polymeric enteric coating encapsulating the surface of the first MSN configured to prevent release of the first bioactive agent in the stomach of the patient, the targeting peptide or the amino acid covalently linked to the first MSN; and
a second pharmaceutical composition combined with the first pharmaceutical composition, wherein the second pharmaceutical composition comprises a second MSN, a second bioactive agent loaded into the second MSN, a polymeric enteric coating encapsulating the surface of the second MSN configured to prevent release of the second bioactive agent in the stomach of the patient, and the targeting peptide or the amino acid covalently linked to the second MSN, wherein the first pharmaceutical composition comprising the first chemotherapeutic agent and the second pharmaceutical composition comprising the second chemotherapeutic agent are combined in a single pill or solution for simultaneous administration.